MaaT Pharma Reports Full Year 2024 Earnings

MaaT Pharma (EPA:MAAT) Full Year 2024 Results

Key Financial Results

• Net loss: €28.9m (loss widened by 47% from FY 2023).

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

All figures shown in the chart above are for the trailing 12 month (TTM) period

MaaT Pharma Earnings Insights

In the last 12 months, the only revenue segment was Oncology Research and Development contributing €3.22m. The largest operating expense was Research & Development (R&D) costs, amounting to €27.7m (86% of total expenses). Explore how MAAT's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 50% p.a. on average during the next 3 years, compared to a 24% growth forecast for the Biotechs industry in France.

Performance of the French Biotechs industry.

The company's shares are up 6.6% from a week ago.

Risk Analysis

You should learn about the 5 warning signs we've spotted with MaaT Pharma.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.